Research Achievements
Decades of research, advancing the next generation of care.
Research into diabetes, hematopoietic stem cells, bone marrow-derived cells, diabetic complications, and regenerative medicine has been building for more than 20 years.
Published in academic journals in Japan and abroad, these findings form the scientific foundation for Biozipcode, Inc.’s current research and development, including studies of abnormal cells associated with persistent diabetes and complete remission in STZ-induced diabetic mice.
Alongside papers and conference presentations, we protect research findings through patents and other intellectual property and develop them into new diagnostic and therapeutic technologies and collaborative projects, with the aim of bringing research into practical use.
Findings from animal models do not establish efficacy or safety in humans. “Diabetes stem cells” (DSCs) is a research concept describing a possible disease mechanism; it is not currently an established category for routine clinical diagnosis.
The patent information describes filed or published international patent families as research outputs. It does not guarantee patent grant status in any country, patent validity, scope of protection, or freedom to operate.
RESEARCH ACHIEVEMENTS
More than 20 years of research, advancing care.
Diabetes, hematopoietic stem cells, bone marrow-derived cells, and cell targeting.
Years of research in these areas provide the scientific foundation for our current work on diabetes stem cells and Biozipcode™.
FROM DISCOVERY TO TRANSLATION
Taking discoveries beyond publication.
Publishing findings, protecting intellectual property, and developing new diagnostic and therapeutic technologies.
Biozipcode, Inc. aims to turn scientific discoveries into care that reaches patients.
OUR RESEARCH FIELDS
Our Main Research Areas
DIABETES STEM CELLS
Diabetes Stem Cells
We study abnormal hematopoietic stem cells and bone marrow-derived cells thought to play a role in the persistence of diabetes and its complications. These are referred to as “diabetes stem cells” (DSCs) for research purposes.
Studies of hematopoietic stem cell abnormalities, epigenetic changes, TNF-α, proinsulin, and CD106 have contributed to this research concept.
DIABETES REMISSION
Research into Complete Diabetes Remission
This research aims for “complete remission”: maintaining normal metabolic function after treatment ends by addressing the processes that sustain diabetes.
Building on a 2023 mouse study, we are investigating translation to humans, biomarkers, and treatment candidates.
DIABETIC COMPLICATIONS
Diabetic Complications
We have studied links between abnormalities in bone marrow-derived cells and tissue damage caused by diabetes across the nervous system, kidneys, blood vessels, skin, liver, bones, and other organs.
This multi-organ research underpins our approach to diabetes as a systemic disorder of cells and tissue repair.
BIOZIPCODE™
Cell Targeting
We identify short peptides that recognize specific cells and tissues and investigate their use in diagnostics, drug delivery systems (DDS), gene delivery, and candidate cell-targeted drugs.
Earlier work on homing peptides for dorsal root ganglia (DRG), the spinal cord, and microglia, as well as gene and siRNA delivery using targeting peptides, has helped build the current Biozipcode™ platform
ONCOLOGY
Cancer Cell Targeting
Using in vivo biopanning and next-generation sequencing (NGS), we seek peptide candidates that bind to cancer cells and tumor tissue while comparing their binding to healthy organs.
We are conducting preclinical studies involving pancreatic and liver cancer and exploring applications for delivering drugs, nucleic acids, and other agents to target tumors.
REGENERATIVE MEDICINE
Tissue Regeneration
We study tissue regeneration technologies that combine cell-targeting peptides with biomaterials to promote the attachment and recruitment of needed cells.
Potential applications include wound healing and regenerative medical materials.
Research Achievements
Explore publications, patents, and conference presentations from years of research into diabetes, hematopoietic stem cells, cell targeting, and related fields.
Explore key publications on diabetes stem cells, diabetic complications, and complete remission research that underpin our R&D.
Explore our intellectual property work in diabetes treatment, diagnostics, abnormal stem cells, and Biozipcode™ to help bring research findings into practical use.
Explore Biozipcode research and activities through research videos, conference presentations, lectures, and seminars.
